Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
Inactivated bluetongue virus, serotype 1, strain ALG2006/01 E1, Inactivated bluetongue virus, serotype 4, strain BTV-4/SPA-1/2004, Inactivated bluetongue virus, serotype 8, strain BEL2006/01
LABORATORIOS SYVA, S.A.U.
QI04AA02
Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 3)
Cattle; Sheep
Inactivated viral vaccines
For active immunisation of sheep to prevent viraemia and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4For active immunisation of cattle to prevent viraemia caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* caused by bluetongue virus serotype 4.
Revision: 3
Authorised
2019-01-09
16 B. PACKAGE LEAFLET 17 PACKAGE LEAFLET : SYVAZUL BTV SUSPENSION FOR INJECTION FOR SHEEP AND CATTLE 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: LABORATORIOS SYVA, S.A.U. Av. Párroco Pablo Diez, 49-57 24010 LEÓN SPAIN Manufacturer responsible for batch release: LABORATORIOS SYVA, S.A.U. Parque Tecnológico de León Av. Portugal s/n Parcelas M15-M16 24009 LEÓN SPAIN 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Syvazul BTV suspension for injection for sheep and cattle 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each ml contains: ACTIVE SUBSTANCES*: Inactivated bluetongue virus (BTV) RP** ≥ 1 * Maximum of two different inactivated bluetongue virus serotypes: Inactivated bluetongue virus, serotype 1 (BTV-1), strain ALG2006/01 E1 Inactivated bluetongue virus, serotype 4 (BTV-4), strain BTV-4/SPA-1/2004 Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01 ** Relative potency measured by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species. The number and type(s) of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label. ADJUVANTS: Aluminium hydroxide (Al 3+ ) 2.08 mg Semi-purified saponin from _Quillaja saponaria_ 0.2 mg 18 EXCIPIENT: Thiomersal 0.1 mg Pinkish-white suspension for injection easily homogenised by shaking. 4. INDICATION(S) Sheep: For active immunisation of sheep to prevent viraemia* and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/ or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes). *Below the level of detection by the validated RT-PCR method at 1.32 log 10 TCID 50 /ml Onset of immunity: 39 days after completion of the primary vaccination s Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Syvazul BTV suspension for injection for sheep and cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCES*: Inactivated bluetongue virus (BTV) RP** ≥ 1 * Maximum of two different inactivated bluetongue virus serotypes: Inactivated bluetongue virus, serotype 1 (BTV-1), strain ALG2006/01 E1 Inactivated bluetongue virus, serotype 4 (BTV-4), strain BTV-4/SPA-1/2004 Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01 ** Relative potency measured by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species. The number and type(s) of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label. ADJUVANTS: Aluminium hydroxide (Al 3+ ) 2.08 mg Semi-purified saponin from _Quillaja saponaria_ 0.2 mg EXCIPIENT: Thiomersal 0.1 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Pinkish-white suspension easily homogenised by shaking. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Sheep and cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Sheep: For active immunisation of sheep to prevent viraemia* and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes). *Below the level of detection by the validated RT-PCR method at 1.32 log 10 TCID 50 /ml Onset of immunity: 39 days after completion of the primary vaccination scheme. 3 Duration of immunity: one year after completion of the primary vaccination scheme. Cattle: For active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* caused by bluetongue virus serotype 4 (combination of maximum 2 seroty Lestu allt skjalið